Codexis, Inc. (Nasdaq:CDXS) announced today that collaborative research conducted by Merck and Codexis scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir has been recently published in the Journal of the American Chemical Society (JACS). Boceprevir is the active ingredient in Merck's VICTRELIS™ (boceprevir) capsules.
“The Codexis technology has delivered solid results including the reduction in production costs for boceprevir,” said Peter Seufer-Wasserthal, Ph.D., Sr. Vice President, Codexis Pharmaceuticals. “This important peer-reviewed publication highlights our continued track record of success in developing innovative, cost effective, practical processes for commercial scale manufacture of therapeutic compounds.”
The JACS publication describes the creation and characterization of a custom enzyme or biocatalyst that was capable of performing a key step in the synthesis of boceprevir. The new method increased chemical intermediate yield 150 percent over the previous process, and reduced raw material use by 60 percent, water use by 61 percent and overall process waste by 63 percent. Codexis used its proprietary CodeEvolver™ directed evolution technology to develop a custom enzyme that can be used in the commercial scale manufacturing of the boceprevir intermediate.
"Incorporation of innovative environmentally sustainable means of manufacture is a key aspect of our research and development strategy," said Richard Tillyer, Ph.D., senior vice president Discovery and Preclinical Sciences, Merck Research Laboratories. "Enzymatic based methods can offer a biodegradable and renewable alternative to currently employed methods."To view the publication, please go to: http://pubs.acs.org/doi/pdf/10.1021/ja3010495 About Codexis, Inc. Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates. Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV